Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTZ3P4W)

• DTT Name: B-cell maturation protein (TNFRSF17) DTT Info
• Gene Name: TNFRSF17

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belantamab mafodotin	DMBT3AI	Multiple myeloma	2A83	Approved	[1]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[2]
Idecabtagene vicleucel	DMP1QTS	Multiple myeloma	2A83	Approved	[3]
Teclistamab	DMGR8JI	Multiple myeloma	2A83	Approved	[4]

62 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciltacabtagene autoleucel	DMU2J7Y	Multiple myeloma	2A83	Phase 3	[5]
Bb2121	DMB0UF9	Multiple myeloma	2A83	Phase 2	[6]
Descartes-08	DM63P1W	Multiple myeloma	2A83	Phase 2	[7]
Descartes-11	DM1UO4S	Multiple myeloma	2A83	Phase 2	[8]
LCAR-B38M CAR-T Cell	DMQZJNA	Multiple myeloma	2A83	Phase 2	[9]
Anti-BCMA CAR-T cells	DM4D3YF	Multiple myeloma	2A83	Phase 1/2	[10]
Anti-BCMA-CAR-transduced T cells	DMZ18IO	leukaemia	2A60-2B33	Phase 1/2	[11]
AUTO2	DM0PWX2	Multiple myeloma	2A83	Phase 1/2	[12]
BCMA CAR T cells	DMH70A9	Multiple myeloma	2A83	Phase 1/2	[13]
BCMA CAR-T	DM1DHPO	Multiple myeloma	2A83	Phase 1/2	[14]
CAR-T cells targeting BCMA	DMENIQ7	leukaemia	2A60-2B33	Phase 1/2	[15]
CART-19/BCMA	DMVW1GY	Multiple myeloma	2A83	Phase 1/2	[16]
CART-BCMA cells	DMWOYNT	Multiple myeloma	2A83	Phase 1/2	[17]
CD38 and BCMA CAR-T Cells	DMFZS8A	Multiple myeloma	2A83	Phase 1/2	[18]
JCARH125	DM8P7FC	Multiple myeloma	2A83	Phase 1/2	[19]
JNJ-68284528	DMD9X6U	Multiple myeloma	2A83	Phase 1/2	[20]
PBCAR269A	DMSGM2L	Multiple myeloma	2A83	Phase 1/2	[21]
REGN5458	DMAGX0Q	Multiple myeloma	2A83	Phase 1/2	[22]
REGN5459	DMRE0LU	Multiple myeloma	2A83	Phase 1/2	[23]
ALLO-715	DMHE3MD	Multiple myeloma	2A83	Phase 1	[24]
AMG 420	DMYFZLA	Multiple myeloma	2A83	Phase 1	[25]
AMG 701	DM6IT3M	Multiple myeloma	2A83	Phase 1	[26]
Anti-BCMA CAR T cells	DM3OFZC	Multiple myeloma	2A83	Phase 1	[27]
Anti-BCMA CAR-T cells	DM2TFUD	Multiple myeloma	2A83	Phase 1	[28]
Anti-BCMA CAR-T cells	DMK25QD	leukaemia	2A60-2B33	Phase 1	[29]
Anti-BCMA CART Cells	DMUKNDO	Multiple myeloma	2A83	Phase 1	[30]
Anti-CD19/BCMA CAR-T cells	DMF93T2	Multiple myeloma	2A83	Phase 1	[31]
Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143	DMKNMAE	Plasma cell myeloma	2A83.1	Phase 1	[32]
Bb21217	DMSBWAQ	Multiple myeloma	2A83	Phase 1	[33]
BCMA CAR-T Cells	DMJ4W5V	Multiple myeloma	2A83	Phase 1	[34]
BCMA CART	DMJ37LH	Multiple myeloma	2A83	Phase 1	[35]
BCMA CART and huCART19	DM2V4EO	Multiple myeloma	2A83	Phase 1	[35]
BCMA nanobody CAR-T cells	DMZDLHV	Multiple myeloma	2A83	Phase 1	[36]
BCMA-CD19 cCAR	DMZ13WQ	Multiple myeloma	2A83	Phase 1	[37]
BCMA-CS1 cCAR	DMEPHMR	Multiple myeloma	2A83	Phase 1	[38]
BCMA-specific CAR-expressing T Lymphocytes	DMW0ZDF	Plasma cell myeloma	2A83.1	Phase 1	[39]
C-CAR088	DMT35N2	Multiple myeloma	2A83	Phase 1	[40]
CAR-T cells targeting BCMA	DMTZADW	Multiple myeloma	2A83	Phase 1	[41]
CART-BCMA	DMVK3M2	Multiple myeloma	2A83	Phase 1	[42]
CART-ddBCMA	DM4OWJ8	Multiple myeloma	2A83	Phase 1	[43]
CC-93269	DM1M4B8	Multiple myeloma	2A83	Phase 1	[44]
CC-98633	DM69YM1	Multiple myeloma	2A83	Phase 1	[45]
CC-99712	DM1UEBR	Multiple myeloma	2A83	Phase 1	[46]
CT053	DMBCJW6	Multiple myeloma	2A83	Phase 1	[47]
CTX120	DMWS40H	Multiple myeloma	2A83	Phase 1	[48]
HPN217	DMI0KQW	Multiple myeloma	2A83	Phase 1	[49]
IM21 CART	DMTNYIB	Multiple myeloma	2A83	Phase 1	[50]
KITE-585	DMXR6HI	Multiple myeloma	2A83	Phase 1	[51]
LCAR-B4822M CAR-T Cell	DMEY2LK	Multiple myeloma	2A83	Phase 1	[52]
MEDI2228	DMX0DUH	Multiple myeloma	2A83	Phase 1	[53]
P-BCMA-101 CAR-T cells	DMDC9TB	Multiple myeloma	2A83	Phase 1	[54]
P-PSMA-101	DMY2GDQ	Prostate cancer	2C82.0	Phase 1	[55]
PHE885	DMBZ2QT	Multiple myeloma	2A83	Phase 1	[56]
RG6296	DMEFUSJ	Multiple myeloma	2A83	Phase 1	[57]
RG6538	DMTRKEB	Multiple myeloma	2A83	Phase 1	[58]
SEA-BCMA	DM7NP1K	Multiple myeloma	2A83	Phase 1	[59]
TNB-383B	DMAI0SH	Multiple myeloma	2A83	Phase 1	[60]
WVT078	DM7MS10	Multiple myeloma	2A83	Phase 1	[61]
BCMA-CART	DMCEPKM	Multiple myeloma	2A83	Clinical trial	[62]
BCMA-UCART	DMWXGRQ	Multiple myeloma	2A83	Clinical trial	[63]
CAR-BCMA T cell	DMLF2UY	Multiple myeloma	2A83	Clinical trial	[64]
CAR-T cells targeting BCMA	DMGW10M	Multiple myeloma	2A83	Clinical trial	[65]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
P-BCMA-ALL01	DMNIM96	Multiple myeloma	2A83	Preclinical	[66]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [4] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
• [5] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
• [8] Clinical pipeline report, company report or official report of Cartesian Therapeutics.
• [9] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [10] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [11] ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
• [12] ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
• [13] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [14] ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma
• [15] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [16] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
• [17] ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
• [18] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [19] ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
• [20] ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
• [21] Clinical pipeline report, company report or official report of Precision Biosciences.
• [22] A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
• [23] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [24] Clinical pipeline report, company report or official report of Allogene Therapeutics.
• [25] Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783.
• [26] Clinical pipeline report, company report or official report of Amgen.
• [27] ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma
• [28] ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
• [29] ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [30] ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
• [31] ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
• [32] ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
• [33] ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma
• [34] ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
• [35] ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
• [36] ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
• [37] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [38] ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [39] ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma
• [40] ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
• [41] ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
• [42] ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma
• [43] Clinical pipeline report, company report or official report of Arcellx.
• [44] T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020 Nov 10;11(45):4076-4081.
• [45] ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [46] ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [47] ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health.
• [48] Clinical pipeline report, company report or official report of CRISPR Therapeutics.
• [49] Clinical pipeline report, company report or official report of AbbVie.
• [50] ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
• [51] ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma
• [52] ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
• [53] A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.
• [54] ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
• [55] Clinical pipeline report, company report or official report of Poseida Therapeutics.
• [56] ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [57] Clinical pipeline report, company report or official report of Genentech.
• [58] Clinical pipeline report, company report or official report of Roche
• [59] ClinicalTrials.gov (NCT03582033) A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.
• [60] Clinical pipeline report, company report or official report of AbbVie.
• [61] ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.
• [62] ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
• [63] ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART
• [64] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• [65] ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
• [66] Clinical pipeline report, company report or official report of Poseida Therapeutics.